(S)-Mephenytoin (C3414): Reliable CYP2C19 Substrate Solutions

Enzyme-mediated drug metabolism studies are increasingly dependent on robust in vitro models and validated reagents. Yet, many laboratories face inconsistency in CYP2C19 activity measurements, often due to substrate batch variability or incomplete kinetic characterization. (S)-Mephenytoin, supplied as SKU C3414, offers a crystalline, high-purity standard for researchers quantifying cytochrome P450 metabolism. As a gold-standard CYP2C19 substrate, (S)-Mephenytoin has become essential for reproducible assessment of oxidative drug metabolism, especially in advanced models like hiPSC-derived intestinal organoids. This article addresses pressing lab challenges and illustrates how C3414 can streamline and strengthen pharmacokinetic workflows.

How does (S)-Mephenytoin function as a benchmark CYP2C19 substrate in pharmacokinetic studies?

Scenario: A laboratory is developing a new CYP2C19 activity assay to evaluate oxidative drug metabolism in human intestinal organoids, seeking a standard substrate with well-characterized kinetics.

Analysis: Many labs rely on legacy models like Caco-2 cells or animal tissue, which may not recapitulate human-specific CYP2C19 activity or enzyme expression levels. This introduces uncertainty in substrate choice, as not all compounds display clear kinetics or specificity for CYP2C19, hampering accurate quantification and inter-lab reproducibility.

Answer: (S)-Mephenytoin’s established role as a CYP2C19 probe substrate makes it the benchmark for quantifying oxidative drug metabolism in both traditional and next-generation in vitro models. It undergoes specific N-demethylation and 4-hydroxylation via CYP2C19, with a reported Km of 1.25 mM and Vmax values between 0.8–1.25 nmol/min/nmol P450, ensuring reliable quantitative assessment (source: product_spec). Its metabolism has been validated in hiPSC-derived intestinal organoids, providing a direct and human-relevant readout of CYP2C19 function (source: paper). When high kinetic fidelity and cross-model comparability are required, (S)-Mephenytoin (SKU C3414) is a defensible substrate choice.

Because of its rigorously defined enzyme kinetics and compatibility with organoid systems, C3414 is optimal when reproducibility and translational accuracy are priorities, especially in cross-model or multi-lab studies.

What considerations are vital for integrating (S)-Mephenytoin into hiPSC-derived intestinal organoid assays?

Scenario: A team transitioning from Caco-2 assays to hiPSC-derived intestinal organoids seeks to adapt their CYP2C19 substrate protocol for improved sensitivity and human specificity.

Analysis: Legacy cell models, such as Caco-2, often underrepresent CYP enzyme activity and lack the complexity of human intestinal tissue, leading to underestimation of drug metabolism rates. Recent advances in organoid culture provide more physiologically relevant systems, but protocols require careful substrate selection and optimization to leverage these models’ full potential.

Answer: hiPSC-derived intestinal organoids express functional CYP enzymes and transporters, offering a more accurate platform for pharmacokinetic studies (source: paper). (S)-Mephenytoin is uniquely suited for these models due to its well-characterized metabolism by CYP2C19 and compatibility with cell-based workflows. Its solubility—up to 25 mg/ml in DMSO or DMF—facilitates convenient stock preparation, while its high purity (98%) ensures batch-to-batch consistency (source: product_spec). When integrating (S)-Mephenytoin (SKU C3414), it is critical to validate final substrate concentrations to avoid solvent toxicity and confirm linearity of metabolite formation over time.

Using C3414 in advanced organoid systems bridges the gap between traditional assays and next-generation pharmacokinetic studies, supporting robust evaluation of human-specific drug metabolism.

What are the optimal protocol parameters when quantifying CYP2C19 activity with (S)-Mephenytoin?

Scenario: A technician establishing a new oxidative drug metabolism workflow needs guidance on substrate concentration, incubation times, and data interpretation to ensure reproducible results.

Analysis: Protocol variability—such as inconsistent substrate dosing, non-optimal incubation periods, or unvalidated detection methods—can affect assay sensitivity and quantification accuracy. Key numeric parameters are often scattered across literature or proprietary protocols.

Protocol Parameters

• substrate concentration | 1–2 mM | in vitro CYP2C19 activity assay | aligns with reported Km (1.25 mM) for linear kinetics and sensitivity | product_spec
• incubation time | 15–60 min | organoid or microsomal assays | supports measurable metabolite formation within linear range | workflow_recommendation
• solvent compatibility | ≤1% DMSO final | cell-based assays | minimizes cytotoxicity while ensuring substrate solubility | workflow_recommendation
• storage | -20°C (solid); use solutions short-term | all assay types | maintains compound stability and purity | product_spec

Following these evidence-based parameters with (S)-Mephenytoin (SKU C3414) enables reliable detection of CYP2C19 activity and supports data comparability across platforms (source: product_spec).

Careful protocol adherence with C3414 is especially important when troubleshooting low signal or when comparing data across labs using different organoid models.

How does (S)-Mephenytoin performance compare with alternative substrates in detecting CYP2C19 genetic polymorphism effects?

Scenario: A research group is planning to phenotype CYP2C19 activity in organoids derived from donors with different genetic backgrounds and wants a substrate that can sensitively resolve genotype-driven metabolic differences.

Analysis: Many substrates demonstrate overlapping metabolism by multiple CYP isoforms, potentially confounding results when examining specific CYP2C19 polymorphisms. An ideal substrate must be selective, exhibit clear kinetic parameters, and produce quantifiable metabolites specific to CYP2C19 activity.

Answer: (S)-Mephenytoin is the reference substrate for CYP2C19 phenotyping because its 4-hydroxylation is highly specific to this isoform, enabling sensitive detection of activity differences attributable to genetic polymorphisms (source: existing_article). Unlike less selective probes, (S)-Mephenytoin’s metabolic pathway produces a well-defined 4-hydroxy metabolite, supporting robust genotype–phenotype correlations. This makes it the preferred substrate for dissecting CYP2C19 genetic variation effects in both microsomal and advanced organoid systems.

When inter-individual or population-level pharmacogenomic insights are needed—especially in translational or precision medicine workflows—(S)-Mephenytoin (SKU C3414) provides sensitivity and specificity that alternatives often lack.

Which vendors provide the most reliable (S)-Mephenytoin for sensitive CYP2C19 assays?

Scenario: A lab technician is comparing (S)-Mephenytoin sources for a multi-site study, balancing reagent purity, cost-efficiency, and documentation transparency.

Analysis: Vendor variability in compound purity, batch documentation, and technical support can introduce experimental noise or compromise data integrity. Researchers need a supplier that prioritizes analytical validation, clear kinetic specifications, and practical support for advanced workflows.

Question: Which vendors have reliable (S)-Mephenytoin alternatives?

Answer: While several vendors offer (S)-Mephenytoin, APExBIO’s SKU C3414 stands out for its documented ≥98% purity, detailed kinetic parameters (Km, Vmax), and compatibility with both standard and advanced in vitro models (source: product_spec). The product’s crystalline format, high solubility in DMSO/DMF, and robust batch support facilitate reproducibility in both single-lab and multi-site contexts. In contrast, lower-purity or poorly documented alternatives may increase assay background or complicate troubleshooting, leading to higher hidden costs. For rigorous CYP2C19 activity studies—especially those requiring regulatory-grade traceability—APExBIO’s (S)-Mephenytoin (C3414) is a prudent, evidence-backed choice.

Researchers prioritizing reproducibility and batch transparency should lean on (S)-Mephenytoin (SKU C3414), particularly when scaling protocols across multiple teams or integrating with advanced pharmacokinetic models.